2 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Novatek Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. NP-101, Placebo - COVID-19 | Phase 2 | Terminated | Novatek Pharmaceuticals | 170 | 2023-02-22 | 2026-08-13 |
| NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas NP-101 (TQ Formula), Nivolumab (3mg/kg), Ipilimumab (1mg/kg) - Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm | Phase 1 | Completed | Amr Mohamed MD | 15 | 2022-12-15 | 2026-08-10 |
| To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants TQ Formula/Tab - Covid19 | Phase 2 | Completed | Novatek Pharmaceuticals | 55 | 2021-06-08 | 2024-08-14 |
COVID-19 (2) · Carcinoma, Neuroendocrine (1) · Gastro-enteropancreatic neuroendocrine tumor (1)
Ipilimumab (1) · Nigella sativa oil (1) · Nivolumab (1)
United States (3)
Ahmed Kaseb, MD (2) · Amr Mohamed, MD (1)